Download PDF
Z Gastroenterol 2006; 44(8): 673-681
DOI: 10.1055/s-2006-926905
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Immuntherapie des Kolorektalkarzinoms - aktueller Stand und Perspektiven

Immunotherapy of Colorectal Cancer - Overview and PerspectivesC. C. Schimanski1 , V. Hörner1 , S. Kanzler1 , P. R. Galle1 , M. Moehler1
  • 11st Department of Medicine, University of Mainz
Further Information

Publication History

Manuskript eingetroffen: 15.3.2006

Manuskript akzeptiert: 7.6.2006

Publication Date:
11 August 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In den letzten Jahrzehnten erzielte die Immuntherapie des Kolonkarzinoms erste wissenschaftliche Fortschritte und entwickelte sich von einer unspezifischen Immunverstärkung über die „aktive spezifische Immuntherapie” zum gezielten immunologischen „Targeting”. Auch wenn Therapieansätze zur Vakzination mit Antigenen oder viralen Vektoren positive Daten zeigen, fehlt der klare Beleg der klinischen Wirksamkeit in großen randomisierten Phase-III-Studien. Parallel werden allgemein anerkannte Analysemethoden benötigt, die bei Patienten die Entwicklung einer therapeutisch effektiven Immunantwort belegen und so die bisher unterschiedlichen Endpunkte in Phase-I/II-Studien vergleichbar machen. Aktuell sind in der palliativen Therapie nur zwei spezifische Antikörper der Rezeptor-Ligandenfamilien der EGF- und VEGF-Signalwege zugelassen, deren immunologische Bedeutung ihrer antikörperabhängigen zellulären Zytotoxizität derzeit analysiert wird.

Abstract

The specific immunotherapy of colorectal cancer initially revealed promising results. However, a significant clinical benefit for patients has still to be proven in phase III trails. In order to compare the different clinical approaches and early phase I - II studies, there is an urgent need for the establishment and acceptance of new standardized diagnostic tools for detecting and quantifying induced and clinical relevant immune responses in patients. Whether or not subgroups with a certain genetic background, such as specific HLA alleles, reveal a better benefit from tumour vaccinations needs to be further analysed. Currently, only two specific antibodies, targeting membraneous receptors or their ligands, such as EGF or VEGF, have been approved by diverse national drug authorities. The question as to whether these antibodies also induce an antibody-dependent cellular toxicity (ADCC) is currently being analysed.

Schlüsselwörter

Kolorektales Karzinom - Immuntherapie - Studien

Key words

Colorectal cancer - clinical trials - immunotherapy

Literatur

  • 1 Agelaki S, Georgoulias V. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.  Expert Opin Emerg Drugs. 2005;  10 (4) 855-874
    CrossrefPubMedGoogle Scholar
  • 2 Albanopoulos K, Armakolas A, Konstadoulakis M M. et al . Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.  Am J Gastroenterol. 2000;  95 (4) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 3 Amin S, Robins R A, Maxwell-Armstrong C A. et al . Vaccine-induced apoptosis: a novel clinical trial end point?.  Cancer Res. 2000;  60 (12) 3132-3136
    PubMedGoogle Scholar
  • 4 Arina A, Tirapu I, Alfaro C. et al . Clinical implications of antigen transfer mechanisms from malignant to dendritic cells exploiting cross-priming.  Exp Hematol. 2002;  30 (12) 1355-1364
    CrossrefPubMedGoogle Scholar
  • 5 Basak S, Eck S, Gutzmer R. et al . Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector.  Ann N Y Acad Sci. 2000;  910 237-252; discussion 252 - 233
    PubMedGoogle Scholar
  • 6 Behrens R J, Achtar M, Herrin V. Phase I/II mutant p53 vaccination in advanced malignancies.  Proc Natl Acad Sci U S A. 2003;  22 186
    PubMedGoogle Scholar
  • 7 Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity.  Trends Immunol. 2002;  23 (4) 201-208
    CrossrefPubMedGoogle Scholar
  • 8 Cartron G, Dacheux L, Salles G. et al . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.  Blood. 2002;  99 (3) 754-758
    CrossrefPubMedGoogle Scholar
  • 9 Conry R M, Allen K O, Lee S. et al . Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.  Clin Cancer Res. 2000;  6 (1) 34-41
    PubMedGoogle Scholar
  • 10 Conry R M, Curiel D T, Strong T V. et al . Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.  Clin Cancer Res. 2002;  8 (9) 2782-2787
    PubMedGoogle Scholar
  • 11 Conry R M, Khazaeli M B, Saleh M N. et al . Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.  Clin Cancer Res. 1999;  5 (9) 2330-2337
    PubMedGoogle Scholar
  • 12 Cunningham D, Humblet Y, Siena S. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 (4) 337-345
    CrossrefPubMedGoogle Scholar
  • 13 Dalerba P, Maccalli C, Casati C. et al . Immunology and immunotherapy of colorectal cancer.  Crit Rev Oncol Hematol. 2003;  46 (1) 33-57
    PubMedGoogle Scholar
  • 14 Fagerberg J, Steinitz M, Wigzell H. et al . Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.  Proc Natl Acad Sci U S A. 1995;  92 (11) 4773-4777
    CrossrefPubMedGoogle Scholar
  • 15 Ferrara N, Hillan K J, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.  Biochem Biophys Res Commun. 2005;  333 (2) 328-335
    CrossrefPubMedGoogle Scholar
  • 16 Feugier P, Van Hoof A, Sebban C. et al . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte.  J Clin Oncol. 2005;  23 (18) 4117-4126
    CrossrefPubMedGoogle Scholar
  • 17 Folprecht G, Lutz M P, Schoffski P. et al . Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.  Ann Oncol. 2006;  17 (3) 450-456
    CrossrefPubMedGoogle Scholar
  • 18 Fong L, Hou Y, Rivas A. et al . Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.  Proc Natl Acad Sci U S A. 2001;  98 (15) 8809-8814
    CrossrefPubMedGoogle Scholar
  • 19 Foon K A, John W J, Chakraborty M. et al . Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.  J Clin Oncol. 1999;  17 (9) 2889-2885
    PubMedGoogle Scholar
  • 20 Ganti A K, Potti A. Epidermal growth factor inhibition in solid tumours.  Expert Opin Biol Ther. 2005;  5 (9) 1165-1174
    CrossrefPubMedGoogle Scholar
  • 21 Ghanekar S A, Nomura L E, Suni M A. et al . Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65.  Clin Diagn Lab Immunol. 2001;  8 (3) 628-631
    CrossrefPubMedGoogle Scholar
  • 22 Gilboa E. The promise of cancer vaccines.  Nat Rev Cancer. 2004;  4 (5) 401-411
    CrossrefPubMedGoogle Scholar
  • 23 Gjertsen M K, Buanes T, Rosseland A R. et al . Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.  Int J Cancer. 2001;  92 (3) 441-450
    CrossrefPubMedGoogle Scholar
  • 24 Goydos J S, Elder E, Whiteside T L. et al . A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.  J Surg Res. 1996;  63 (1) 298-304
    CrossrefPubMedGoogle Scholar
  • 25 Habal N, Gupta R K, Bilchik A J. et al . CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.  Ann Surg Oncol. 2001;  8 (5) 389-401
    PubMedGoogle Scholar
  • 26 Hanahan D, Lanzavecchia A, Mihich E. Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors.  Cancer Research. 2003;  63 (11) 3005-3008
    PubMedGoogle Scholar
  • 27 Hanna M GJ, Hoover H CJ, Vermorken J B. et al . Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.  Vaccine. 2001;  21 (19) 2576-2582
    PubMedGoogle Scholar
  • 28 Harris J E, Ryan L, Hoover Jr H C. et al . Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.  J Clin Oncol. 2000;  18 (1) 148-157
    PubMedGoogle Scholar
  • 29 Himmler G, Schuster M, E n nn J. Murine monoclonal antibody 17 - 1A used as a vaccine antigen: Direct induction of anti-EpCAM antibodies by vaccination of cancer patients.  Proc Am Soc Clin Oncol. 2003;  22 183
    PubMedGoogle Scholar
  • 30 Hoover Jr H C, Brandhorst J S, Peters L C. et al . Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.  J Clin Oncol. 1993;  11 (3) 390-399
    PubMedGoogle Scholar
  • 31 Horig H, Lee D S, Conkright W. et al . Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.  Cancer Immunol Immunother. 2000;  49 (9) 504-514
    PubMedGoogle Scholar
  • 32 Ibrahim R A, Herrin V, Gause B. Mutant p53 vaccination of patients with advanced cancers generates specific immunological responses.  Proc Natl Acad Sci U S A. 2004;  22 2521
    PubMedGoogle Scholar
  • 33 Igney F H, Krammer P H. Immune escape of tumors: apoptosis resistance and tumor counterattack.  J Leukoc Biol. 2002;  71 (6) 907-920
    PubMedGoogle Scholar
  • 34 Karanikas V, Thynne G, Mitchell P. et al . Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.  J Immunother. 2001;  24 (2) 172-183
    PubMedGoogle Scholar
  • 35 Klinman D M. CpG DNA as a vaccine adjuvant.  Expert Rev Vaccines. 2003;  2 (2) 305-315
    CrossrefPubMedGoogle Scholar
  • 36 Laurie J a, Moertel C G, Fleming T R. et al . Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.  Journal of Clinical Oncology. 1990;  7 1447-1456
    PubMedGoogle Scholar
  • 37 Liang W, Wang H, Sun T M. et al . Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.  World J Gastroenterol. 2003;  9 (3) 495-498
    PubMedGoogle Scholar
  • 38 Liebrich W, Schlag P, Manasterski M. et al . In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.  Eur J Cancer. 1991;  27 (6) 703-710
    PubMedGoogle Scholar
  • 39 Liu K J, Wang C C, Chen L T. et al . Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.  Clin Cancer Res. 2004;  10 (8) 2645-2651
    CrossrefPubMedGoogle Scholar
  • 40 Loibner H, Eller N, Groiss F. A randomized placebo-controlled phase II study with cancer vaccine IGN101 in patients with epithelial solid organ tumors.  Proc Natl Acad Sci U S A. 2004;  22 14-16
    PubMedGoogle Scholar
  • 41 MacLean G D, Reddish M A, Koganty R R. et al . Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.  J Immunother Emphasis Tumor Immunol. 1996;  19 (1) 59-68
    PubMedGoogle Scholar
  • 42 Marshall J L, Gulley J L, Arlen P M. et al . Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.  J Clin Oncol. 2005;  23 (4) 720-731
    CrossrefPubMedGoogle Scholar
  • 43 Marshall J L, Hoyer R J, Toomey M A. et al . Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.  J Clin Oncol. 2000;  18 (23) 3964-3973
    PubMedGoogle Scholar
  • 44 Matsuda K, Tsunoda T, Tanaka H. et al . Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells.  Cancer Immunol Immunother. 2004;  53 (7) 609-616
    PubMedGoogle Scholar
  • 45 Maxwell-Armstrong C A, Durrant L G, Buckley T J. et al . Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.  Br J Cancer. 2001;  84 (11) 1443-1446
    CrossrefPubMedGoogle Scholar
  • 46 Mazzaferro V, Coppa J, Carrabba M G. et al . Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.  Clin Cancer Res. 2003;  9 (9) 3235-3245
    PubMedGoogle Scholar
  • 47 Mellstedt H, Fagerberg J, Frodin J E. et al . Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.  Curr Opin Hematol. 1999;  6 (3) 169-175
    CrossrefPubMedGoogle Scholar
  • 48 Menon A G, Kuppen P J, van der Burg S H. et al . Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.  Cancer Gene Ther. 2003;  10 (7) 509-517
    CrossrefPubMedGoogle Scholar
  • 49 Miyagi Y, Imai N, Sasatomi T. et al . Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.  Clin Cancer Res. 2001;  7 (12) 3950-3962
    PubMedGoogle Scholar
  • 50 Moehler M, Teufel A, Galle P R. New chemotherapeutic strategies in colorectal cancer.  Recent Results Cancer Res. 2005;  165 250-259
    PubMedGoogle Scholar
  • 51 Morse M A, Nair S K, Mosca P J. et al . Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.  Cancer Invest. 2003;  21 (3) 341-349
    CrossrefPubMedGoogle Scholar
  • 52 Mosolits S, Markovic K, Frodin J E. et al . Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.  Clin Cancer Res. 2004;  10 (16) 5391-5402
    CrossrefPubMedGoogle Scholar
  • 53 Moulton H M, Yoshihara P H, Mason D H. et al . Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.  Clin Cancer Res. 2002;  8 (7) 2044-2051
    PubMedGoogle Scholar
  • 54 Mukohara T, Engelman J A, Hanna N H. et al . Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.  J Natl Cancer Inst. 2005;  97 (16) 1185-1194
    PubMedGoogle Scholar
  • 55 Neidhart J, Allen K O, Barlow D L. et al . Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.  Vaccine. 2004;  22 (5/6) 773-780
    PubMedGoogle Scholar
  • 56 Ockert D, Schirrmacher V, Beck N. et al . Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.  Clin Cancer Res. 1996;  2 (1) 21-28
    PubMedGoogle Scholar
  • 57 Parkin D M, Bray F, Ferlay J. et al . Estimating the world cancer burden: Globocan 2000.  Int J Cancer. 2001;  94 (2) 153-156
    CrossrefPubMedGoogle Scholar
  • 58 Punt C J, Nagy A, Douillard J Y. et al . Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.  Lancet. 2002;  360 (9334) 671-677
    CrossrefPubMedGoogle Scholar
  • 59 Riemer A B, Kurz H, Klinger M. et al . Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.  J Natl Cancer Inst. 2005;  97 (22) 1663-1670
    PubMedGoogle Scholar
  • 60 Riethmuller G, Holz E, Schlimok G. et al . Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial.  Journal of Clinical Oncology. 1998;  16 (5) 1788-1794
    PubMedGoogle Scholar
  • 61 Romond E H, Perez E A, Bryant J. et al . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.  N Engl J Med. 2005;  353 (16) 1673-1684
    CrossrefPubMedGoogle Scholar
  • 62 Sadanaga N, Nagashima H, Mashino K. et al . Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.  Clin Cancer Res. 2001;  7 (8) 2277-2284
    PubMedGoogle Scholar
  • 63 Saleh M N, LoBuglio A F. et al . A phase II trial of murine monoclonal antibody 17 - 1A and interferon-gamma: clinical and immunological data.  Cancer Immunol Immunother. 1990;  32 (3) 185-190
    PubMedGoogle Scholar
  • 64 Samonigg H, Wilders-Truschnig M, Kuss I. et al . A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.  J Immunother. 1999;  22 (6) 481-488
    PubMedGoogle Scholar
  • 65 Sehn L H, Donaldson J, Chhanabhai M. et al . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.  J Clin Oncol. 2005;  23 (22) 5027-5033
    CrossrefPubMedGoogle Scholar
  • 66 Slack R, Chang P, Arlen P. Association between CEA-specific T-cell responses following treatment with vaccina-CEA and ALVAC-CEA and survival in patinets with CEA-bearing cancers.  Proc Natl Acad Sci U S A. 2001;  20 272A
    PubMedGoogle Scholar
  • 67 Staib L, Birebent B, Somasundaram R. et al . Immunogenicity of recombinant GA733 - 2E antigen (CO17 - 1A, EGP, KS1 - 4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.  Int J Cancer. 2001;  92 (1) 79-87
    CrossrefPubMedGoogle Scholar
  • 68 Tartour E, Benchetrit F, Haicheur N. et al . Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols.  Vaccine. 2002;  20 (4) 32-39
    CrossrefPubMedGoogle Scholar
  • 69 Thieme H, Aiello L P, Takagi H. et al . Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells.  Diabetes. 1995;  44 (1) 98-103
    PubMedGoogle Scholar
  • 70 Tsang K Y, Zaremba S, Nieroda C A. et al . Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.  J Natl Cancer Inst. 1995;  87 (13) 982-990
    PubMedGoogle Scholar
  • 71 Tsuruma T, Hata F, Torigoe T. et al . Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.  J Transl Med. 2004;  2 (1) 19
    CrossrefPubMedGoogle Scholar
  • 72 Ueda Y, Itoh T, Nukaya I. et al . Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.  Int J Oncol. 2004;  24 (4) 909-917
    PubMedGoogle Scholar
  • 73 Ullenhag G J, Frodin J E, Jeddi-Tehrani M. et al . Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.  Clin Cancer Res. 2004;  10 (10) 3273-3281
    CrossrefPubMedGoogle Scholar
  • 74 Ullenhag G J, Frodin J E, Mosolits S. et al . Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response.  Clin Cancer Res. 2003;  9 (7) 2447-2456
    PubMedGoogle Scholar
  • 75 Vermorken J B, Claessen A M, van Tinteren H. et al . Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.  Lancet. 1999;  353 (9150) 345-350
    CrossrefPubMedGoogle Scholar
  • 76 von Mehren M, Arlen P, Gulley J. et al . The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.  Clin Cancer Res. 2001;  7 (5) 1181-1191
    PubMedGoogle Scholar
  • 77 von Mehren M, Arlen P, Tsang K Y. et al . Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.  Clin Cancer Res. 2000;  6 (6) 2219-2228
    PubMedGoogle Scholar
  • 78 Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.  Semin Oncol. 2001;  28 (1 Suppl 1) 9-13
    PubMedGoogle Scholar
  • 79 Wolmark N, Fisher B, Rockette H. et al . Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.  J Natl Cancer Inst. 1988;  80 (1) 30-36
    PubMedGoogle Scholar
  • 80 Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.  Ann Oncol. 2005;  16 847-862
    CrossrefPubMedGoogle Scholar

PD Dr. med. Markus Möhler

1. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität, Mainz

Langenbeckstr. 1

55101 Mainz

Phone: ++49/61 31/1 70

Fax: ++49/61 31/17 34 38

Email: moehler@mail.uni-mainz.de

      >